KOL Insight Archives | Page 12 of 14 | Report Store

Acute Lymphocytic Leukemia KOL Interview

[Newer treatments] are definitely being used in the relapse population, and that’s where they made their mark like most other investigational agents for other cancers. I think the issue is that the response rate with initial induction therapy is so high. Whether or not there is going to be a maintenance-type study strategy, that’s a question with some of these therapies that are relatively low toxicity, but when you have a complete remission rate of 90-95%, and ALL’s not the most common disease – it’s a pretty rare cancer actually – that it’s going to be difficult to do large studies for indications in the randomized setting.

KOL Insight

Acute Lymphocytic Leukemia KOL Interview

Triple Negative Breast Cancer KOL Interview

Datamonitor Schizophrenia KOL Interview

Datamonitor Schizophrenia KOL Interview 2

Treatment of VTE – US KOL Interview

Treatment of VTE – EU KOL Interview

2015 Jardiance EMPA-REG CVOT Pulse

Intersection Between Tech and Pharma KOL Interview

Drug Pricing and Market Access KOL Interview

2015 Breast Cancer Pulse #3

Ebola KOL Interview #3

Post-AASLD US KOL Interview

2014 Community-Acquired Pneumonia Pulse

Asthma and COPD KOL Interview

Pneumococcal Vaccines KOL Interview